Wilms' Tumor

Many children with cancer experience emotional distress, fatigue, and difficulties in relationships. Their parents also face increased responsibilities and may feel more distressed and tired. While psychological interventions for these families have shown promise in improving social skills, coping, and well-being, further research is needed. Hypnosis is commonly used in pediatric oncology to reduce pain and distress during procedures and has also been effective in enhancing well-being in adults with cancer. This trial explores the feasibility and potential benefits of combining self-care and hypnosis in a group setting for children with cancer and their parents. The intervention involves six monthly group sessions, each lasting two hours, where participants learn self-hypnosis exercises and discuss self-care techniques like understanding personal needs, self-respect, assertiveness, and managing negative thoughts. Homework assignments are given to encourage positive changes. Two groups participate one including children with cancer and their siblings, and another for their parents. Data are collected before and after the intervention through questionnaires and interviews to assess its impact. Participants will complete assessments measuring changes in childrens quality of life, fatigue related to cancer, and parents perceptions of their childs quality of life and their own fatigue. Secondary outcomes include the impact of cancer on the family, parents emotional distress, and coping strategies. These are evaluated before the program starts and immediately after its conclusion at six months. The study aims to improve understanding of how this combined self-care and hypnosis intervention may enhance the well-being of children with cancer and their families.

Sleep plays a vital role in a childs development, affecting brain function, emotional health, and overall recovery. Children undergoing intensive cancer treatments often experience sleep problems such as difficulty falling or staying asleep, shorter sleep duration, or poor sleep quality. These issues, reported in a significant portion of pediatric cancer survivors, can impact treatment adherence, daily life, and social interactions, highlighting the need for better sleep management in this group. Researchers are evaluating the Dreamcatchers Programme, a nurse-led, multi-component intervention designed to improve sleep quality in children with cancer. The program involves sleep hygiene education, progressive muscle relaxation PMR, and breathing exercises, delivered through group sessions and weekly follow-ups over four weeks. The intervention group receives these targeted strategies, while the control group continues routine hospital support without sleep-specific content, with access to the program after the study. Participants will attend initial education sessions, practice relaxation techniques, and keep sleep diaries to track habits and progress. Nurses will monitor sleep quality and overall life quality at three months using validated tools. Data will be collected securely and confidentiality maintained. This pilot study aims to assess feasibility and provide preliminary effectiveness results to guide future pediatric oncology sleep care.

Researchers are evaluating CBA-1205, an anti-DLK1 monoclonal antibody, in a first-in-human Phase I study involving patients with advanced solid tumors, hepatocellular carcinoma HCC, malignant melanoma, and pediatric cancers. The study aims to assess the safety and tolerability of CBA-1205 across five parts, including dose escalation and evaluation in different patient groups where standard treatments are unavailable or ineffective. This trial is conducted at multiple centers and is non-randomized and open-label. Participants receive CBA-1205 intravenously at two-week intervals in 28-day cycles. The study includes seven dose cohorts ranging from 0.1 mgkg to 30 mgkg for solid tumors in Part 1, with subsequent parts focusing on specific cancers such as HCC, melanoma, and pediatric cancers. Treatment continues until criteria for discontinuation are met. Pharmacokinetic analysis is also part of the evaluation. During the study, participants will undergo safety monitoring for dose-limiting toxicities and adverse events up to 12 months. Blood samples will be collected to measure serum drug concentration and immunogenicity. Efficacy assessments occur at screening, during treatment cycles, and until treatment discontinuation. Overall, participant involvement includes regular visits for treatment administration and comprehensive monitoring throughout the study duration.

Researchers are evaluating the SYSUCC-RMS regimen for children with rhabdomyosarcoma, a type of pediatric cancer. This study aims to understand how effective and safe this treatment is, while also exploring how combining radiotherapy with chemotherapy affects survival rates across different risk groups low, medium, high, and very high risk. The study is a Phase 3 clinical trial led by Yizhuo Zhang. Participants receive one of several combination chemotherapy regimens based on their risk level low risk patients receive VAC, intermediate risk patients receive VACVII, high risk patients receive CAVIE, and very high risk patients receive CAVVIP. The study follows a single-arm design and evaluates the treatments over various risk groups, focusing on the impact of concurrent therapies on survival. During the study, researchers will monitor participants for up to 10 years, assessing outcomes such as objective response rate, disease control rate, progression-free survival, and overall survival. Safety of the SYSUCC-RMS regimen will also be tracked throughout this period. Participants health status will be regularly evaluated to understand the long-term effects and treatment outcomes.

Researchers are evaluating how well combination chemotherapy works in treating patients with newly diagnosed stages 2 to 4 diffuse anaplastic Wilms tumor DAWT and patients with relapsed favorable histology Wilms tumor FHWT. This phase II trial compares the effects of two chemotherapy regimens, UH-3 and ICECycloTopo, on event-free survival and overall survival, aiming to improve outcomes based on different relapse risk groups and prior treatments. The study also explores kidney toxicity, genetic markers, surgery impacts, and radiation therapy techniques to reduce side effects and better understand tumor behavior. Participants are assigned to one of two treatment groups. In Arm I Regimen UH-3, patients receive cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan intravenously over various days in a 21-day cycle, with radiation therapy at week 7 of cycle 3 if needed. In Arm II Regimen ICECycloTopo, patients receive cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan intravenously over 10 cycles every 21 days, with surgery andor radiation therapy during certain cycles as clinically indicated. Throughout the trial, patients undergo multiple imaging tests including CT scans, PET scans, chest x-rays, MRIs, abdominal ultrasounds, and bone scans, along with blood sample collections and biopsies. After completing treatment, follow-up visits occur every 3 months for the first 2 years, then every 6 months for years 3 and 4, and once at year 5. The main outcomes measured are event-free survival and overall survival up to 5 years from study entry, with ongoing monitoring for treatment effects and safety.

Researchers are evaluating selinexor as a potential treatment for people with relapsed or refractory Wilms tumor, rhabdoid tumor, malignant peripheral nerve sheath tumors MPNST, BCOR-driven sarcomas, or other solid tumors that produce higher than normal levels of the XPO1 protein or have genetic changes that increase XPO1 activity. This phase II study aims to understand selinexors effectiveness in these specific pediatric solid tumors, sponsored by Memorial Sloan Kettering Cancer Center. The study treats participants with selinexor at a pediatric recommended phase 2 dose of 35 mgm2 once weekly using a liquid form, with a maximum dose of 100 mg per dose. Participants are divided into cohorts based on their tumor type, including Wilms tumor, rhabdoid tumor, MPNST, other solid tumors showing potential benefit from selinexor, and BCOR-driven sarcomas. Each cohort follows the same treatment schedule, and some patients may be enrolled in pharmacokinetic cohorts depending on their age. During the study, participants will undergo assessments to monitor their disease status, including measurable disease evaluations using standardized criteria. Researchers will track the overall response rate six months after treatment begins to determine the treatments impact. Participants must meet specific health criteria, including adequate organ function and performance status. The study includes informed consent, safety monitoring, and follows participants until the end of the treatment period, which may last several months.

Researchers are studying children aged 5 to 18 years who have solid cancer or blood-related cancers to understand how intense physical activities or stretching affect insulin sensitivity and other metabolic, motor, and nutritional factors. The study aims to observe whether intense physical activity improves these health measures compared to a stretching program. Children are included at the start of their cancer treatment, with a focus on their first treatment experience and a life expectancy exceeding six months. The study involves two different physical activity programs lasting six months one intense adapted physical activity combining aerobics and muscle strengthening, and another stretching program. Children participate in sessions two to three times a week, either during hospital stays or via videoconference at home. The intense activity sessions last 30 minutes for younger children and 60 minutes for older children. Evaluations occur at the beginning, at three and six months during the program, and follow-ups are done six and eighteen months after the programs end. Participants will undergo metabolic, motor, and nutritional assessments at scheduled time points throughout the study and after completion. The research team will monitor insulin sensitivity as the main outcome. Children receive personalized physical activity sessions adapted to their abilities and preferences. The overall participation lasts up to about two years, including initial treatment and follow-up evaluations to track the long-term effects of the physical activity programs.

This research aims to understand how follow-up care is managed for survivors of childhood cancer in Switzerland as they move from pediatric to adult healthcare. It focuses on adolescent and young adult survivors who have completed cancer treatment and are living with potential late effects. The study compares three different transition models to find out which best meets survivors needs and helps maintain regular follow-up care. Participants are part of a multicenter study involving three pediatric oncology centers in Switzerland. Survivors receive questionnaires about their cancer knowledge, worries, self-management skills, ongoing care, and expectations related to their follow-up care. Questionnaires are sent before and after their transition to adult care, with follow-ups at three and fifteen months to track changes over time. During the study, participants complete several questionnaires assessing their readiness for transition and knowledge about their cancer history. The study measures cancer worry, self-management, ongoing care needs, and expectations at baseline, three months, and fifteen months. Data helps improve transition strategies, aiming for better adherence to adult follow-up care. The total participation time covers these assessments over more than a year, supporting long-term survivor care.

Researchers are investigating a treatment for children, adolescents, and young adults with relapsed or refractory solid tumors. The study evaluates the safety and potential survival benefits of an allogeneic stem cell transplant depleted of alphabeta T cells and CD19 B cells combined with zoledronic acid. This approach aims to enhance the immune systems graft versus tumor effect and improve event-free and overall survival rates in these patients. Participants receive a stem cell transplant processed using the Miltenyi CliniMACS Prodigy system to remove specific immune cells. Zoledronic acid is given intravenously on days 28, 56, 84, 112, and 140 post-transplant. The study includes a phase Ib dose-finding portion to determine the maximum tolerated dose of zoledronic acid, followed by a phase II portion where all subjects receive this dose. During the trial, participants are closely monitored through various assessments including disease-free survival and incidence of acute graft-versus-host disease at multiple time points up to two years after transplant. The research team evaluates overall survival rates at 100 days, 1 year, and 2 years post-transplant. The study spans several years, with participants undergoing treatment and follow-up evaluations to track safety and effectiveness.

This research aims to evaluate the Antimfcllerian Hormone AMH as a predictor of infertility risk in children with cancer or benign diseases treated with chemotherapy andor pelvic irradiation. It focuses on girls aged 3 to 14 years, including prepubertal and pubertal patients, who are classified into high, moderatelow, and no risk groups based on their treatments potential impact on ovarian reserve. The study addresses the challenge of assessing ovarian reserve and fertility preservation needs in young patients who progress normally through puberty but may have impaired ovarian function due to treatment. Participants are observed over several years with no intervention administered as part of the study. They are grouped by their risk category high risk those receiving conditioning therapy for bone marrow transplantation or pelvic irradiation, moderatelow risk patients treated with chemotherapy regimens associated with varying risks, and no risk patients with benign or malignancies not involving gonadotoxic treatment. Assessments include measuring AMH levels and other hormones before and after treatment and during follow-up visits up to 18 years old. During the study, participants undergo evaluations at inclusion, end of treatment, annually for the first three years, and then every two years until age 18. These include blood tests for ovarian reserve hormones AMH, FSH, estradiol, testosterone, LH, pubertal stage assessments using TANNER criteria, menstrual cycle monitoring, and bone age evaluation via X-rays. Researchers will use these measurements to identify patients at risk of premature ovarian failure and to better understand how chemotherapy affects ovarian function in relation to pubertal status.